As of 2026-05-26, the EV/EBITDA ratio of Austar Lifesciences Ltd (6118.HK) is 14.81. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. 6118.HK's latest enterprise value is 544.09 mil HKD. 6118.HK's TTM EBITDA according to its financial statements is 36.73 mil HKD. Dividing these 2 quantities gives us the above 6118.HK EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 13.2x - 17.3x | 15.0x |
| Forward P/E multiples | 8.7x - 12.5x | 10.4x |
| Fair Price | 0.83 - 3.41 | 1.89 |
| Upside | 3.6% - 325.7% | 136.0% |
| Date | EV/EBITDA |
| 2026-05-22 | 79.05 |
| 2026-05-21 | 80.00 |
| 2026-05-20 | 80.00 |
| 2026-05-19 | 79.05 |
| 2026-05-18 | 79.05 |
| 2026-05-15 | 79.05 |
| 2026-05-14 | 79.05 |
| 2026-05-13 | 79.05 |
| 2026-05-12 | 78.10 |
| 2026-05-11 | 80.95 |
| 2026-05-08 | 80.95 |
| 2026-05-07 | 81.90 |
| 2026-05-06 | 80.95 |
| 2026-05-05 | 80.00 |
| 2026-05-04 | 78.10 |
| 2026-04-30 | 79.05 |
| 2026-04-29 | 76.21 |
| 2026-04-28 | 76.21 |
| 2026-04-27 | 79.05 |
| 2026-04-24 | 79.05 |
| 2026-04-23 | 79.05 |
| 2026-04-22 | 81.90 |
| 2026-04-21 | 81.90 |
| 2026-04-20 | 80.00 |
| 2026-04-17 | 80.00 |
| 2026-04-16 | 80.00 |
| 2026-04-15 | 83.80 |
| 2026-04-14 | 79.05 |
| 2026-04-13 | 79.05 |
| 2026-04-10 | 79.05 |
| 2026-04-09 | 82.85 |
| 2026-04-08 | 80.95 |
| 2026-04-02 | 79.05 |
| 2026-04-01 | 79.05 |
| 2026-03-31 | 80.95 |
| 2026-03-30 | 80.00 |
| 2026-03-27 | 80.00 |
| 2026-03-26 | 71.46 |
| 2026-03-25 | 71.46 |
| 2026-03-24 | 71.46 |
| 2026-03-23 | 66.72 |
| 2026-03-20 | 71.46 |
| 2026-03-19 | 69.57 |
| 2026-03-18 | 70.52 |
| 2026-03-17 | 74.31 |
| 2026-03-16 | 74.31 |
| 2026-03-13 | 74.31 |
| 2026-03-12 | 72.41 |
| 2026-03-11 | 75.26 |
| 2026-03-10 | 71.46 |